How much is the oral proteins and peptides market worth, and how is it expected to expand?
The oral proteins and peptides market size has grown exponentially in recent years. It will grow from $1.27 $ billion in 2024 to $1.56 $ billion in 2025 at a compound annual growth rate (CAGR) of 22.7%. The growth in the historic period can be attributed to the rising prevalence of chronic diseases, increasing investments in biotechnology for the development of oral protein-based treatments, growing consumer preference for non-invasive treatments, increasing biopharmaceutical industry, and rising focus on personalized medicine.
The oral proteins and peptides market size is expected to see exponential growth in the next few years. It will grow to $3.49 $ billion in 2029 at a compound annual growth rate (CAGR) of 22.3%. The growth in the forecast period can be attributed to increasing focus on patient-centric drugs, increasing prevalence of the geriatric population, rising healthcare expenditure, growing need for diagnostics in cancer, and rising preference for oral drugs. Major trends in the forecast period include development of novel oral peptides with enhanced stability and efficacy, integration of artificial intelligence in drug discovery processes for oral formulations, advanced medical treatments, advancements in drug delivery technologies, and innovative oral insulin formulations.
Get Your Free Sample of The Global Oral Proteins And Peptides Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp
Which industry factors have accelerated the oral proteins and peptides market’s expansion?
The growing biopharmaceutical industry is expected to propel the growth of the oral proteins and peptides market going forward. The biopharmaceutical industry is a sector within the broader pharmaceutical industry that focuses on developing, producing, and commercializing drugs derived from biological sources. The growth of the biopharmaceutical industry is due to advancements in biotechnology, growing demand for personalized medicine, increasing prevalence of chronic diseases, and rising investment in research and development. Oral proteins and peptides in biopharmaceuticals offer potential for non-invasive delivery of therapeutics, enhancing patient compliance and reducing the need for injections. They can target specific diseases with improved stability and absorption in the digestive system. For instance, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based European trade association representing the pharmaceutical industry, the total bio-pharmaceutical production in Europe accounted for $384,200 million (€340,000 million) in 2022, an increase of approximately 4.95% from $366,267 million (€323,950 million) in 2021. Therefore, the growing biopharmaceutical industry is driving the growth of the oral proteins and peptides market.
What are the primary segments of the oral proteins and peptides market?
The oral proteins and peptidesmarket covered in this report is segmented –
1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide
2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Oxalate, Other Biological Targets
3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action
4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer
Subsegments:
1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)
2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment
3) By Insulin: Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations
4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)
5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report
Which firms are leading the oral proteins and peptides market?
Major companies operating in the oral proteins and peptides market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.
Which market trends are set to define the future of the oral proteins and peptides market?
Major companies operating in the oral proteins and peptides market are focusing on developing innovative products, such as Oral Semaglutide, to enhance patient adherence and comfort. Oral semaglutide is a groundbreaking medication that significantly advances oral proteins and peptides. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, traditionally administered via injection to treat type 2 diabetes and, more recently, obesity. For instance, in January 2022, Novo Nordisk India, an India-based healthcare company, launched the world’s first oral semaglutide, marking a revolutionary advance in diabetes treatment. Semaglutide is a GLP-1 receptor analogue (GLP-1 RA) previously available only in injectable form, now offers a more convenient oral option for managing type 2 diabetes. This breakthrough not only transforms diabetes care but also sets the stage for future innovations in oral insulin formulations, potentially leading to more effective and patient-friendly treatment options.
Which geographic trends are shaping the oral proteins and peptides market, and which region has the highest market share?
North America was the largest region in the oral proteins and peptides market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Oral Proteins And Peptides Market Report 2025 Offer?
The oral proteins and peptides market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Oral Proteins and Peptides refer to therapeutic proteins and peptides administered orally, typically in pills, capsules, or other ingestible formats. These biologically active molecules are designed to treat various medical conditions by leveraging their specific actions within the body.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19629
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
